|[December 19, 2013]
Research and Markets: Global Menotropin Market 2012-2016: One of the Major Drivers is the Increasing Cases of Infertility
DUBLIN --(Business Wire)--
Research and Markets (http://www.researchandmarkets.com/research/2rgwjh/global_menotropin)
has announced the addition of the "Global
Menotropin Market 2012-2016" report to their offering.
The analysts forecast the Global Menotropin market to grow at a CAGR of
1.315 percent over the period 2012-2016. One of the key factors
contributing to this market growth is the increasing number of
infertility cases. The Global Menotropin market has also been witnessing
an increasing number of awareness programs on the prevention and
treatment of infertility. However, the adverse side effects of
menotropins could pose a challenge to the growth of this market.
The key vendors dominating this space Ferring Pharmaceuticals Inc. and
Merck Serono S.A.
The other vendors mentioned in the report are Angelini Farmaceutica
S.A.,Bharat Serums and Vaccines Ltd., Emcure Pharmaceuticals Ltd., Fuji
Yakuhin Co. Ltd., GP-Pharm S.A., LG Life Sciences India Pvt. Ltd.,
Mochida Pharmaceutical Co. Ltd., Neiss Labs Ltd., Sanzyme Ltd., Win
Medicare Pvt. Ltd., and Zydus Cadila Healthcare Ltd.
Commenting on the report, an analyst from the Healthcare team said: The
most common trend in the Global Menotropin market is the increase in the
number of awareness programs regarding the prevention and treatment of
infertility. These programs are conducted by various governmental and
non-governmental organizations. For instance, The National Infertility
Association celebrates National Infertility Awareness Week worldwide
from April 21 to 27. Such awareness campaigns are educating people about
the various technologies available to treat infertility. Moreover, Merck
Serono, which produces numerous drugs used to treat fertility, embarked
on a campaign in April 2013 called "Hope for Starting Families" to
increase awareness on infertility and its treatment in the Philippines.
Such awareness programs are expected to trigger the growth of the market.
Further, the report states that the availability of alternative
treatment options such as other fertility drugs, IVF procedures,
surrogacy, and intracytoplasmic sperm injection is hampering the growth
of the Global Menotropin market. The key drug therapies include
clomiphene citrate, hCG, GnRH antagonists, hMG, and FSH. All these
therapies that are available to treat infertility in women are highly
efficacious and safe.
For more information visit http://www.researchandmarkets.com/research/2rgwjh/global_menotropin
About Research and Markets
Research and Markets is the world's leading source for international
market research reports and market data. We provide you with the latest
data on international and regional markets, key industries, the top
companies, new products and the latest trends.
[ Back To Technology News's Homepage ]